Results 91 to 100 of about 7,735 (172)

Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence, Risk Factors at a Tertiary Care Hospital in Nepal: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Epistaxis is a common complication associated with oral anticoagulant and antiplatelet therapies, often leading to significant morbidity. In recent years, the incidence of cardiovascular disease in Nepal has risen dramatically, driving a widespread use of these medications and heightened concerns regarding bleeding ...
Shiv Kumar Sah, Ashok Kumar Gupta, Sanjaya Acharya, Suraj Kumar Thakur, Rajkumar Chaudhary, Shiva Pandeya, Arjun Budthapa, Vijaya K. C., Sajish Khadgi, Manjita Bajracharya   +9 more
wiley   +1 more source

Dabigatran etexilate [PDF]

British Journal of Clinical Pharmacology, 2010
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

PLoS ONE, 2015
IntroductionThe fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of ...
Joachim Kuhn, Tatjana Gripp, Tobias Flieder, Marcus Dittrich, Doris Hendig, Jessica Busse, Cornelius Knabbe, Ingvild Birschmann   +7 more
doaj   +1 more source

Neurocardiology: Brain–Heart Interactions in the Heart

MedComm, Volume 7, Issue 9, September 2026.
The heart and brain maintain systemic homeostasis through bidirectional communication involving neural, biochemical, and mechanical pathways. Dysregulation of these pathways contributes to a spectrum of conditions involving heart–brain interactions, including Takotsubo syndrome, the epileptic heart, stroke–heart syndrome, heart failure, cardiac ...
Wentao Wang, Hao Jia, Han Han, Jiangping Song   +3 more
wiley   +1 more source

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice

, 2015
Michael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of ...
Reyes M, Preusch MR, Ieronimakis N, Bea F, van Ryn J, Wijelath ES, Rosenfeld ME, Cabbage S, Ricks J   +8 more
core  

Secondary Analysis: Odds of Switching to Dabigatran after ODBP listing of Dabigatran–Adjusted Model.

, 2016
Secondary Analysis: Odds of Switching to Dabigatran after ODBP listing of Dabigatran–Adjusted Model.
Michelle Sholzberg (2513476), David N. Juurlink (259072), Tara Gomes (563908), Zhan Yao (2513473), Andreas Laupacis (39520), Muhammad M. Mamdani (259064)   +5 more
core   +1 more source

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study

Drugs - Real World Outcomes, 2019
Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin.
Hui-Min Diana Lin, Chao-Lun Lai, Yaa-Hui Dong, Yu-Kang Tu, K. Arnold Chan, Samy Suissa   +5 more
doaj   +1 more source

Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 9, September 2026.
The clinical manifestations of PFO. Although the majority of PFOs are benign and asymptomatic, they can present with a variety of clinical manifestations, or coexisting with other diseases and aggravating their symptoms, including cerebral diseases (such as CS, epilepsy, TIA, or migraine), systemic embolism (such as embolism in renal artery, coronary ...
Linlin Meng, Xiaotong Zhang, Guangrui Sun, Honggang Dai, Xiao Meng, Cheng Zhang, Yun Zhang   +6 more
wiley   +1 more source

Primary Analysis: Odds of Switching to Dabigatran Prior to ODBP listing of Dabigatran–Adjusted Model.

, 2016
Primary Analysis: Odds of Switching to Dabigatran Prior to ODBP listing of Dabigatran–Adjusted Model.
Michelle Sholzberg (2513476), David N. Juurlink (259072), Tara Gomes (563908), Zhan Yao (2513473), Andreas Laupacis (39520), Muhammad M. Mamdani (259064)   +5 more
core   +1 more source

Integrating CRRT as a Virtual Organ Into Physiologically Based Pharmacokinetic Modeling to Optimize Antimicrobial Dosing in Septic Patients

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
Development and application of PBPK modeling integrating CRRT as a virtual organ to characterize antimicrobial pharmacokinetics and optimize dosing in septic patients. ABSTRACT Continuous renal replacement therapy (CRRT) extracorporeal drug removal, sepsis‐related pathophysiological alterations, and reduced pathogen susceptibility to antimicrobials can
Yuanming Xing, Yijing Zhang, Chuqi Bai, Yulan Qiu, Chuhui Wang, Lei Chen, Taotao Wang, Jiaojiao Chen   +7 more
wiley   +1 more source